Funding for this research was provided by:
Bayer HealthCare (Donation of moxifloxacin)
AIDS Clinical Trials Group
National Institutes of Health
United States Agency for International Development
National Institute of Allergy and Infectious Diseases (1U01AI069469, 1U01AI069453, 1U01AI069426, UM1AI068634, UM1 AI068636, and UM1AI106701)
Department of Foreign Affairs and Trade, Australian Government
European and Developing Countries Clinical Trials Partnership (IP.2007.32011.011)
Sanofi (Donation of rifampicin)
Bill and Melinda Gates Foundation (OPP1017459)
Department for International Development
Directorate General for International Cooperation of the Netherlands
Received: 12 March 2018
Accepted: 10 September 2018
First Online: 17 October 2018
: MM—UCL Clinician and Research Associate; GW—Statistician, MRC Clinical Trials Unit at UCL; SM—Clinician and Research Associate, UCL; CL—Clinician and Principal Investigator, Madibeng Centre for Research, South Africa; AB—Post-doctoral Scientist, UCL; RH—Senior Research Associate, UCL; TDM—Professor of Clinical Microbiology, UCL, and Director, UCL Centre for Clinical Microbiology; AJN—Senior scientist at MRC Clinical Trials Unit at UCL; SKM—Professor of Clinical Trials, MRC Clinical Trials Unit at UCL; CM—Senior VP Research and Development, TB Alliance; MS—President and CEO, TB Alliance; AC—Senior Statistician, MRC Clinical Trials Unit at UCL; SHG—Sir James Black Professor of Medicine, University of St Andrews.
: The UCL ethics committee and the ethics committees of all study sites and organisations approved the REMoxTB study; these are provided in the Additional file InternalRef removed. Patients gave their informed consent for the REMoxTB study and for their specimens and data to be used for the purposes of this study [CitationRef removed].
: All authors have given their consent to publication and have agreed to the authorship and order of authorship for this manuscript.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.